Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label momelotinib extension study in myelofibrosis, polycythemia vera, or essential thrombocythemia
2013-004476-36Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mivavotinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), myelofibrosis (MF) and 2 more, sponsored by Gilead Sciences. Primary endpoint: Safety. Started Oct 2014; status: completed.
02
Drugs
mivavotinib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)myelofibrosis (MF)polycythemia vera (PV)thrombocythemia
Beyond the preview
Go deeper on 2013-004476-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004476-36.